Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty

Trial Profile

An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Precocious puberty
  • Focus Adverse reactions
  • Sponsors Takeda

Most Recent Events

  • 23 Dec 2021 Results assessing efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children published in the Medicine
  • 19 Dec 2018 Status changed from active, no longer recruiting to completed.
  • 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 31 Dec 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top